JP2018535230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535230A5 JP2018535230A5 JP2018526784A JP2018526784A JP2018535230A5 JP 2018535230 A5 JP2018535230 A5 JP 2018535230A5 JP 2018526784 A JP2018526784 A JP 2018526784A JP 2018526784 A JP2018526784 A JP 2018526784A JP 2018535230 A5 JP2018535230 A5 JP 2018535230A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- inhibitor
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- DXOJUCNAHCVBRU-UHFFFAOYSA-N 2-amino-3-(3,4-dihydroxyphenyl)propanamide Chemical compound NC(=O)C(N)CC1=CC=C(O)C(O)=C1 DXOJUCNAHCVBRU-UHFFFAOYSA-N 0.000 claims 5
- 229960004205 carbidopa Drugs 0.000 claims 5
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 4
- 108010062431 Monoamine oxidase Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 3
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 3
- 150000002337 glycosamines Chemical class 0.000 claims 3
- 229960003194 meglumine Drugs 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000019430 Motor disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 1
- 206010001541 Akinesia Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 1
- 102000006378 Catechol O-methyltransferase Human genes 0.000 claims 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 101710116650 FAD-dependent monooxygenase Proteins 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 208000005903 Manganese Poisoning Diseases 0.000 claims 1
- 206010027439 Metal poisoning Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 101710128228 O-methyltransferase Proteins 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 229910002090 carbon oxide Inorganic materials 0.000 claims 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000002183 duodenal effect Effects 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 229960003337 entacapone Drugs 0.000 claims 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical group CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical group C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004644 moclobemide Drugs 0.000 claims 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 1
- 230000007659 motor function Effects 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229960000245 rasagiline Drugs 0.000 claims 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims 1
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 claims 1
- 229950002652 safinamide Drugs 0.000 claims 1
- 229960003946 selegiline Drugs 0.000 claims 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 229960004603 tolcapone Drugs 0.000 claims 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259324P | 2015-11-24 | 2015-11-24 | |
| US62/259,324 | 2015-11-24 | ||
| PCT/IL2016/051261 WO2017090039A2 (en) | 2015-11-24 | 2016-11-23 | Pharmaceutical compositions comprising levodopa amide and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018535230A JP2018535230A (ja) | 2018-11-29 |
| JP2018535230A5 true JP2018535230A5 (OSRAM) | 2019-12-26 |
Family
ID=57590758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526784A Pending JP2018535230A (ja) | 2015-11-24 | 2016-11-23 | レボドパアミドを含む医薬組成物およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170296491A1 (OSRAM) |
| EP (1) | EP3380076A2 (OSRAM) |
| JP (1) | JP2018535230A (OSRAM) |
| CN (1) | CN108495617A (OSRAM) |
| AU (1) | AU2016358511A1 (OSRAM) |
| BR (1) | BR112018010564A2 (OSRAM) |
| CA (1) | CA3006028A1 (OSRAM) |
| CL (1) | CL2018001395A1 (OSRAM) |
| IL (1) | IL259484A (OSRAM) |
| RU (1) | RU2018119194A (OSRAM) |
| SG (1) | SG11201804395PA (OSRAM) |
| WO (1) | WO2017090039A2 (OSRAM) |
| ZA (1) | ZA201803485B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106413754B (zh) | 2014-03-13 | 2019-11-29 | 纽罗德姆有限公司 | 多巴脱羧酶抑制剂组合物 |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| WO2019038637A1 (en) | 2017-08-21 | 2019-02-28 | Neuroderm Ltd | FORMS OF CRYSTALLINE SALT OF LEVODOPA AMIDE AND METHODS OF MAKING AND USING THEM |
| AR112473A1 (es) | 2017-08-21 | 2019-10-30 | Neuroderm Ltd | Proceso para preparar amida de levodopa purificada |
| WO2019038639A1 (en) | 2017-08-21 | 2019-02-28 | Neuroderm Ltd | FREE LEOPODOPA CRYSTALLINE AMIDE BASE AND METHODS OF MAKING AND USING SAME |
| WO2019145773A1 (en) | 2017-12-15 | 2019-08-01 | Nos Life Sciences Corporation | Liposomal-encapsulated formulations |
| WO2020178810A1 (en) * | 2019-03-04 | 2020-09-10 | Neuroderm, Ltd. | Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof |
| WO2020214886A1 (en) * | 2019-04-17 | 2020-10-22 | Vici Health Sciences LLC | Liquid pharmaceutical compositions |
| MX2022002787A (es) * | 2019-09-05 | 2022-06-16 | Neuroderm Ltd | Composiciones liquidas que comprenden un conjugado de aminoacidos de levodopa y usos de estas. |
| JP7506371B2 (ja) * | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | ドーパミン減少抑制剤 |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| CN116270675A (zh) * | 2023-03-21 | 2023-06-23 | 山东省分析测试中心 | N-乙酰氨基葡萄糖在防治mptp诱导神经元损伤中的应用 |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1596808A4 (en) * | 2003-02-07 | 2007-04-04 | Yissum Res Dev Co | L-DOPA AMID DERIVATIVES AND THEIR USE |
| RU2678839C2 (ru) | 2009-05-19 | 2019-02-04 | Неуродерм Лтд | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
| SG191090A1 (en) * | 2010-12-10 | 2013-07-31 | Synagile Corp | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| US20150217046A1 (en) * | 2012-06-05 | 2015-08-06 | Synagile Corporation | Dosing regimens for subcutaneously infusible acidic compositions |
-
2016
- 2016-11-23 BR BR112018010564-3A patent/BR112018010564A2/pt not_active IP Right Cessation
- 2016-11-23 CN CN201680079822.0A patent/CN108495617A/zh not_active Withdrawn
- 2016-11-23 WO PCT/IL2016/051261 patent/WO2017090039A2/en not_active Ceased
- 2016-11-23 RU RU2018119194A patent/RU2018119194A/ru not_active Application Discontinuation
- 2016-11-23 CA CA3006028A patent/CA3006028A1/en not_active Abandoned
- 2016-11-23 AU AU2016358511A patent/AU2016358511A1/en not_active Abandoned
- 2016-11-23 JP JP2018526784A patent/JP2018535230A/ja active Pending
- 2016-11-23 EP EP16816418.4A patent/EP3380076A2/en not_active Withdrawn
- 2016-11-23 US US15/360,165 patent/US20170296491A1/en not_active Abandoned
- 2016-11-23 SG SG11201804395PA patent/SG11201804395PA/en unknown
-
2018
- 2018-05-21 IL IL259484A patent/IL259484A/en unknown
- 2018-05-24 CL CL2018001395A patent/CL2018001395A1/es unknown
- 2018-05-25 ZA ZA2018/03485A patent/ZA201803485B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535230A5 (OSRAM) | ||
| RU2018119194A (ru) | Фармацевтические композиции, содержащие амид леводопы, и их применения | |
| CN113906013A (zh) | 吡啶氮氧化合物及其制备方法和用途 | |
| EA201391730A1 (ru) | 3,5-диамино-6-хлор-n-(n-(4-(4-(2-(гексил(2,3,4,5,6-пентагидроксигексил)амино)этокси)фенил)бутил) карбамимидоил)пиразин-2-карбоксамид | |
| JP2015511958A5 (OSRAM) | ||
| JP2009143956A5 (OSRAM) | ||
| JP2013541514A5 (OSRAM) | ||
| CL2019001066A1 (es) | Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854) | |
| CN109311812A (zh) | 作为c-MET抑制剂的吡啶酮类化合物 | |
| ME02177B (me) | Supstituisani derivati ksantina | |
| JP2015536337A5 (OSRAM) | ||
| JP2019510082A5 (OSRAM) | ||
| TN2012000352A1 (en) | Use of an adrenal hormone-modifying agent | |
| JP2017521436A5 (OSRAM) | ||
| JP2015110646A5 (OSRAM) | ||
| JP2014511374A5 (OSRAM) | ||
| WO2018125983A8 (en) | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors | |
| UA110696C2 (uk) | 7-[3,5-дигідрокси-2-(3-гідрокси-5-фенілпент-1-еніл)циклопентил]-n-етилгепт-5-енамід (біматопрост) у кристалічній формі ii, спосіб його одержання й спосіб його застосування | |
| UA105649C2 (uk) | Хінолонова сполука і фармацевтична композиція | |
| NZ709199A (en) | Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds | |
| WO2012093411A3 (en) | Process for the preparation of r-(-)-3- (carbamoylmethyl)-5-methylhexanoic acid and the intermediates | |
| GEP20247683B (en) | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof | |
| JP2017226652A5 (OSRAM) | ||
| JP2019527468A5 (OSRAM) | ||
| JP2018536645A5 (OSRAM) |